Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3961MR)

This product GTTS-WQ3961MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3961MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4499MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ968MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ898MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ9803MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ15613MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ14861MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ632MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10603MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW